Literature DB >> 32432700

Return to sports after COVID-19 infection.

Philipp Schellhorn1, Karin Klingel2, Christof Burgstahler1.   

Abstract

Entities:  

Year:  2020        PMID: 32432700      PMCID: PMC7314071          DOI: 10.1093/eurheartj/ehaa448

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


× No keyword cloud information.

Introduction

Current coronavirus disease (COVID-19) has grown into a pandemic crisis of major health and economic importance. An infection with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is known to cause severe respiratory symptoms up to an acute respiratory distress syndrome (ARDS), but also often involves the cardiovascular system,1,2 which is associated with increased mortality.3 The highest mortality rates were observed in patients with underlying cardiovascular disease and co-existing elevated cardiac troponin levels.4 In particular, elevated serum levels of cardiac troponin and inflammatory biomarkers (i.e. interleukin-6 and serum ferritin) were characteristic for cases with severe illness and non-survivors.4–8 This high inflammatory burden in COVID-19, described as a hyperinflammatory response, is considered to be co-responsible for development of ARDS, vascular inflammation, myocarditis, and myocarditis-related cardiac events, e.g. arrhythmias.6,7 However, many individuals have only mild or no symptoms despite being infected.

Are athletes at risk for COVID-19?

Despite the fact that athletes do not belong to the risk group for severe COVID-19, numerous individuals and occasionally entire sports teams have been affected by COVID-19 infections.9,10 In this context, the question arises of to what extent a SARS-CoV-2 infection with or without symptoms can affect eligibility for sport, particularly the point of return to training or competition. Still, due to their, on average, young age and good general health, it can be assumed that the frequency of mild or asymptomatic persons will be significantly higher in this subgroup when compared with the general public. Nevertheless, a potential risk of a myocardial involvement cannot be excluded even in asymptomatic athletes. Keep in mind that myocarditis is one of the leading causes of sport-associated sudden cardiac death in the group of athletes under 35 years of age.11 The clinical presentation of myocarditis in general shows a wide and heterogenic spectrum of symptoms. Athletes frequently present with non-specific symptoms such as fatigue, malaise, reduced performance, muscle soreness, or increased resting heart rate, which can often be misinterpreted in the context of other differential diagnoses (e.g. training-related exhaustion/overtraining, depression, or psychosomatic disorders). Thus, athletes are often not subjected to a COVID-19 test (e.g. nasopharyngeal swab), so that the diagnosis of a COVID-19 infection and a potential COVID-19-associated myocardial involvement or myocarditis cannot be made. In this case, further diagnostic or therapeutic measures can be delayed or even completely neglected.

Myocarditis associated with COVID-19 in athletes

In the reports of severe COVID-19 cases, data on cardiac examinations are often missing. However, a report by Inciardi et al.,12 describing the case of an otherwise healthy 53-year-old white woman with cardiac involvement, lists numerous diagnostic anomalies. Remarkably, cardiac pathology developed 1 week after recovering from influenza-like symptoms. Moreover, there are reported cases of sudden cardiac death in non-hospitalized COVID-19-positive individuals with only mild symptoms.13 Descriptions of mild COVID-19-associated myocarditis are very rare or even non-existent. Nevertheless, in the assessment of eligibility for participation in sport for athletes in recovery from COVID-19, these might be very helpful for further risk stratification and for guiding reintegration to training and competition. COVID-19-associated cardiac injury and its long-term consequences in athletes could be significantly underestimated if the assessment of cardiac injury is defined merely by the presence of elevated troponins.14,15 The assessment of suspected myocarditis in athletes, especially those with mild or no symptoms, can be difficult. Even in cases of a variety of abnormal diagnostic results, myocarditis cannot always be diagnosed with certainty. For example, alterations in the ECG can also be explained by long-term training adaptation.16 Similarly, elevated cardiac biomarkers such as troponin or creatine kinase may also be explained by acute exercise.20 Typical presentation of athletes with suspected myocarditis in the outpatient setting differs from that commonly observed in a hospital setting, specifically regarding the significantly greater frequency of milder disease severity. Athletes are usually highly sensitive to subtle changes in their physical condition or performance. This includes symptoms such as prolonged time to recover, fatigue, or peripheral muscle soreness. The symptoms of COVID-19 are often non-specific, too.17 The difficulty in interpretation of such non-specific symptoms in combination with an unclear diagnosis results from the variety of possible differential diagnoses such as mild myocarditis, COVID-19 without cardiac involvement, or sport-associated symptoms such as fatigue and muscle pain.

Highlighting the diagnostic dilemma in athletes

In summary there is currently insufficient data available to describe the presentation of clinically mild COVID-associated myocarditis or even to predict its long-term outcome. With regard to consultations with non-specific symptoms in sports medicine outpatient clinics, the differential diagnosis of a past COVID-19 infection and/or a COVID-19-associated myocarditis should be taken into consideration, perhaps even retrospectively, where appropriate. The COVID-19 outbreak and its cardiovascular involvement support the need for further research to fill the currently large gaps of knowledge, particularly with regard to immediate and long-term cardiovascular implications of viral infections in athletes.

What do we know from previous outbreaks of respiratory virus infections?

Data from previous epidemics of corona species [SARS-CoV 2002 or Middle Eastern respiratory syndrome (MERS)-CoV 2012] revealed a significant association between underlying cardiovascular disease, myocardial injury, and worse outcomes.13,18 SARS-CoV might manifest as hypotension, cardiac arrhythmias, and sudden cardiac death.19,20 Data obtained in a rabbit model suggest that coronavirus can induce cardiomyopathy, resulting in dilated cardiac chambers and systolic impairment.21 Reversible cardiomegaly with no clinical evidence of heart failure was also reported in a small group of humans.22 Some of the clinical manifestations, such as sinus tachycardia22 or persistent abnormalities of lipid (68%) and glucose metabolism (60%), as well as cardiovascular abnormalities (40%) at 12-year follow-up, appear to persist beyond the acute phase of infection.23 Currently, we do not know whether COVID-19 has the potential to cause myocarditis and myocarditis-associated long-term consequences even in mild cases. Above all, it is unclear how to rate COVID-19-associated risks in comparison with previous influenza or (other) corona epidemics.

Eligibility for sport in situations of possible myocardial involvement

The question of how to deal with athletes following COVID-19 and how to reintegrate them safely into sports is difficult to answer at the moment. A helpful orientation for guiding clinical processes are the recommendations proposed by the European Society of Cardiology, the American Heart Association/American College of Cardiology, or the 36th Bethesda Conference (2005).24–27 Whether this approach is also applicable in COVID-19-associated myocarditis is presently unclear. In any case, a careful follow-up of athletes recovering from the current COVID-19 should be performed. As patients with COVID-19 have been reported to develop cardiovascular complications even in the absence of underlying cardiovascular disease, prospective data collection via registries such as CAPACITY-COVID28 appears to be an important approach. An initial strategy might be to adapt the above-mentioned general recommendations for a return to sport in athletes with (suspected) myocarditis.24–27 We suggest the following approach shown in Figure . Proposed algorithm for a return to sport for an athlete with positive test result of SARS-CoV-2 or with typical COVID-19 symptoms. Abbreviations: ECG, electrocardiogram; COVID-19, coronavirus disease. From other virus infections, it is known that viral replication can be enhanced during vigorous activity, resulting in greater structural damage of the heart tissue.29,30 Thus, in the case of an athlete diagnosed with COVID-19, but without any symptoms, we would also recommend refraining from intensive or competitive-like exercise for at least 2 weeks. In the absence of symptoms and abnormalities in the resting ECG at the end of this time period, return to sport can be recommended without restriction. In any case of myocarditis, a strict ban on sport for a period of at least 3–6 months is recommended based on animal data suggesting a virulence-promoting effect of exercise.29,30 Following the above-mentioned recommendations,24–27 return to training and competition appears to be reasonable if left ventricular function and cardiac dimensions have returned to normal, if clinically relevant arrhythmias are absent in Holter ECG monitoring and exercise test, and if serum markers of inflammation and heart failure have normalized. In symptomatic COVID-19-positive athletes with no diagnostic evidence of myocarditis, following sport restriction for at least 2–4 weeks, a thorough medical examination (physical examination, resting and exercise ECG, and echocardiography) should be performed before resuming sports activities. Return to sport will be possible in the absence of abnormal results. It is known that the prognosis of athletes with uncomplicated acute myocarditis and with a complete recovery, including normalized left ventricular function and absence of late gadolinium enhancement, is highly favourable.31,32 Still, in athletes recovering from COVID-19, even without pre-existing diseases, the development of cardiovascular complications and long-term consequences, e.g. arrhythmias, must be taken into consideration and should be ruled out by means of a careful follow-up. In the near future, data about treatment and monitoring of athletes recovering from COVID-19 will be of major importance. Above all, specifically against the background of the wide spectrum of COVID-19 disease manifestations, the questions of eligibility for sport and long-term consequences of COVID-19 for athletes should be addressed.

Summary

The cardiovascular effects and long-term consequences of COVID-19 are currently unclear. The question of eligibility for sport and the point of return to sport following both asymptomatic and symptomatic COVID-19 with or without suspected involvement of the myocardium is currently becoming more and more important in leisure as well as in competitive sports. Fortunately, from previous studies and registries of acute myocarditis, it has been known that athletes with a complete recovery have a very good prognosis. Nevertheless, to optimize counselling and treatment of athletes in the future, prospective data collection on the current corona pandemic is urgently needed. To this end, the non-evidence-based recommendations for a return to sports presented herein might serve as a first guideline.

References

References are available as Supplementary material at European HeartJournal online. Click here for additional data file.
  18 in total

1.  [Guideline S1: Long COVID: Diagnostics and treatment strategies].

Authors:  Susanne Rabady; Johann Altenberger; Markus Brose; Doris-Maria Denk-Linnert; Elisabeth Fertl; Florian Götzinger; Maria de la Cruz Gomez Pellin; Benedikt Hofbaur; Kathryn Hoffmann; Renate Hoffmann-Dorninger; Rembert Koczulla; Oliver Lammel; Bernd Lamprecht; Judith Löffler-Ragg; Christian A Müller; Stefanie Poggenburg; Hans Rittmannsberger; Paul Sator; Volker Strenger; Karin Vonbank; Johannes Wancata; Thomas Weber; Jörg Weber; Günter Weiss; Maria Wendler; Ralf-Harun Zwick
Journal:  Wien Klin Wochenschr       Date:  2021-12-01       Impact factor: 1.704

2.  A prospective study on the consequences of SARS-CoV-2 infection on the heart of young adult competitive athletes: Implications for a safe return-to-play.

Authors:  Luna Cavigli; Federica Frascaro; Francesca Turchini; Nicola Mochi; Patrizio Sarto; Stefano Bianchi; Antonio Parri; Nicolò Carraro; Serafina Valente; Marta Focardi; Matteo Cameli; Marco Bonifazi; Flavio D'Ascenzi
Journal:  Int J Cardiol       Date:  2021-05-31       Impact factor: 4.164

3.  Resumption of Sport at the United States Olympic and Paralympic Training Facilities During the COVID-19 Pandemic.

Authors:  Ankit B Shah; Dustin Nabhan; Robert Chapman; George Chiampas; Jonathan Drezner; J Tod Olin; David Taylor; Jonathan T Finnoff; Aaron L Baggish
Journal:  Sports Health       Date:  2021-03-12       Impact factor: 3.843

Review 4.  Cardiovascular Involvement in COVID-19: What Sequelae Should We Expect?

Authors:  Maria Vincenza Polito; Angelo Silverio; Michele Bellino; Giuseppe Iuliano; Marco Di Maio; Carmine Alfano; Patrizia Iannece; Nicolino Esposito; Gennaro Galasso
Journal:  Cardiol Ther       Date:  2021-06-30

5.  Comment on: "The Challenge of Maintaining Metabolic Health During a Global Pandemic".

Authors:  Lino Sérgio Rocha Conceição; Cristiane Vilaça Campos Gomes; Vitor Oliveira Carvalho
Journal:  Sports Med       Date:  2020-11       Impact factor: 11.136

Review 6.  Perspectives on the Impact of the COVID-19 Pandemic on the Sports Medicine Surgeon: Implications for Current and Future Care.

Authors:  Kyle N Kunze; Peter D Fabricant; Robert G Marx; Benedict U Nwachukwu
Journal:  Clin Sports Med       Date:  2020-08-22       Impact factor: 2.182

Review 7.  Coronavirus Disease 2019: Cardiac Complications and Considerations for Returning to Sports Participation.

Authors:  Daniel X Augustine; Tracey Keteepe-Arachi; Aneil Malhotra
Journal:  Eur Cardiol       Date:  2021-03-02

8.  'Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria.

Authors:  Bodunrin Osikomaiya; Olufemi Erinoso; Kikelomo Ololade Wright; Aina Olufemi Odusola; Babafemi Thomas; Oluwatosin Adeyemi; Abimbola Bowale; Olusola Adejumo; Ayodeji Falana; Ismail Abdus-Salam; Olusegun Ogboye; Akin Osibogun; Akin Abayomi
Journal:  BMC Infect Dis       Date:  2021-03-25       Impact factor: 3.090

9.  Season Suspension and Summer Extension: Unique Opportunity for Professional Team-Sport Athletes and Support Staff During and Following the COVID-19 Crisis.

Authors:  Thomas Huyghe; Stephen Bird; Julio Calleja-González; Pedro E Alcaraz
Journal:  Front Sports Act Living       Date:  2020-07-07

10.  Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review.

Authors:  Mohammad Said Ramadan; Lorenzo Bertolino; Rosa Zampino; Emanuele Durante-Mangoni
Journal:  Clin Microbiol Infect       Date:  2021-06-23       Impact factor: 13.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.